Results 201 to 210 of about 78,474 (272)

Efficacy of high-dose vs. low-dose intravitreal ganciclovir for cytomegalovirus retinitis: a systematic review and meta-analysis. [PDF]

J Yeungnam Med Sci
Jeong S, Jeong A, Do JR, Kang YK, Sagong M.   +4 more
europepmc   +1 more source

Outcomes of Ab-Interno Canaloplasty and Gonioscopy-Assisted Transluminal Trabeculotomy in Eyes with Sustained Intraocular Pressure Elevation Following Intravitreal Injections. [PDF]

Clin Ophthalmol
Gallardo MJ, Porter M, Vincent L, Sandrosyan A, Koch B, Kasuga DT.   +5 more
europepmc   +1 more source

Neuritin1 Cis-Regulatory Elements Enable Gene Expression Preferentially in Retinal Ganglion Cells. [PDF]

Invest Ophthalmol Vis Sci
Talla V, Koilkonda R, Kinane C, Panchal M, Khuu T, Park KK.   +5 more
europepmc   +1 more source

Real-world efficacy and safety of Brolucizumab injection in vitrectomised eyes (BIVE) - a prospective multicentric study. [PDF]

BMC Ophthalmol
Boral SK, Agarwal D, Chakraborty D, Das A, Sinha TK.   +4 more
europepmc   +1 more source

Clinical effectiveness of the 0.18 mg fluocinolone acetonide intravitreal implant for non-infectious uveitis-associated macular edema: a real-world study. [PDF]

BMC Ophthalmol
Chen C, Zhang WJ, Ding Q, Shen SM, Ye Y, Huang Z, Yan M, Song YP.   +7 more
europepmc   +1 more source

Primary vitreoretinal lymphoma: diagnostic and therapeutic insights from a Slovenian population-based study. [PDF]

Int J Retina Vitreous
Vrabič N, Boltežar L, Panjan M, Prevodnik VK, Mekjavič PJ, Vidmar MS, Klobučar P, Petrovič MG, Valentinčič NV.   +8 more
europepmc   +1 more source

Pharmacological Treatment for Diabetic Macular Edema: A 2025 Update on Durability and Multi-Target Therapies. [PDF]

Drug Des Devel Ther
Tao Y, Zhang Y, Xu W, Liu G, Liu H.
europepmc   +1 more source

Long-Term Intravitreal Dexamethasone Implant Monotherapy in Naïve Patients with Diabetic Macular Edema. [PDF]

Turk J Ophthalmol
Karataş G, Çakır A, Aday Ö, Uzundede T, Kırık F, Özoğuz AM, Özdemir H, Elçioğlu MN.   +7 more
europepmc   +1 more source

Reducing the Carbon Footprint of Neovascular Age-Related Macular Degeneration Therapy: Environmental Impact of Transitioning to Aflibercept 8 mg. [PDF]

J Ophthalmol
Veritti D, Misciagna M, Teatino C, Pontoni C, Blasutig M, Kuftic M, Pece S, Morsanutto A, Pece A, Lanzetta P.   +9 more
europepmc   +1 more source

Off-label intravitreal brolucizumab and bevacizumab for chronic central serous chorioretinopathy. [PDF]

Int J Ophthalmol
Joo JY, Jun YH, Kim ST.
europepmc   +1 more source